- Repligen (NASDAQ:RGEN) entered into an agreement with Purolite Life Sciences to supply its next-generation Protein A ligand, NGL-Impact A.
- Tony J. Hunt, Repligen CEO, said, “We are delighted by this agreement with Purolite Life Sciences, which is a natural extension of our existing Protein A supply agreement with them. We look forward to seeing how this next-generation ligand performs in the marketplace with Purolite Life Sciences’s Praesto jetted agarose bead technology.”
- Press Release
Repligen selects Purolite Life Sciences as commercial partner for new high performance ligand
Recommended For You
More Trending News
About RGEN Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
RGEN | - | - |
Repligen Corporation |